Investor Webinar Presentation
On 12 August 2026, Arovella hosted an investor webinar for shareholders and interested parties.
The webinar provided an update following the Board of Directors’ recent strategic review of the Company, including its priorities for advancing Arovella’s iNKT cell therapy platform, the near-term clinical development of ALA-101 and the Company’s broader opportunity to build shareholder value via pipeline expansion into solid tumour and autoimmune disease indications.
The presentation was delivered by Chairman, Dr David Williams, and Acting CEO, Dr Nicole van der Weerden, and also covered progress toward the Company’s Phase 1 first-in-human trial of ALA-101, which is expected to dose the first patient in September 2026.